Claims
- 1. A method for treating vaginismus, the method comprising administering to a patient in need thereof a compound selected from the group consisting of calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, cAMP-dependent protein kinase activators, superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators and adenylyl cyclase activators.
- 2. The method of claim 1, wherein said method comprises administering to said patient at least two compounds.
- 3. The method of claim 1, wherein said method further comprises administering to said patient a second compound selected from the group consisting of NO donors, phosphodiesterase inhibitors, cGMP-dependent protein kinase activators and cGMP mimetics.
- 4. The method of claim 1, wherein said compound is an α-adrenergic receptor antagonist.
- 5. The method of claim 4, wherein said α-adrenergic receptor antagonist is a member selected from the group consisting of α1-adrenergic receptor antagonists and α2-adrenergic receptor antagonists.
- 6. The method of claim 5, wherein said α-adrenergic receptor antagonist is an α2-adrenergic receptor antagonist.
- 7. The method of claim 1, wherein said compound is a potassium channel activator.
- 8. The method of claim 7, wherein said potassium channel activator is an ATP-sensitive potassium channel activator.
- 9. The method of claim 7, wherein said potassium channel activator is a Maxi-K channel activator.
- 10. The method of claim 1, wherein said compound is a cholinergic modulator.
- 11. The method of claim 10, wherein said cholinergic modulator is a member selected from the group consisting of acetylcholine storage blocking agents and acetylcholine vesicle transport blocking agents.
- 12. The method of claim 1, wherein said compound is administered orally.
- 13. The method of claim 1, wherein said compound is administered parenterally.
- 14. The method of claim 1, wherein said compound is administered topically.
- 15. The method of claim 14, wherein said compound is in a form selected from the group consisting of gel, ointment, cream, lotion, powder, solution, suspension, spray, paste, oil, suppository, and foam.
- 16. The method of claim 1, wherein said compound is delivered continuously.
- 17. The method of claim 16, wherein a vaginal suppository or a ring impregnated with said compound is inserted at the affected site.
- 18. A method for treating dyspareunia, the method comprising administering to a patient in need thereof a compound selected from the group consisting of cholinergic modulators, α-adrenergic receptor antagonists, cAMP-dependent protein kinase activators, superoxide scavengers, potassium channel activators, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators and adenylyl cyclase activators.
- 19. The method of claim 18, wherein said method comprises administering to said patient at least two compounds.
- 20. The method of claim 18, wherein said method further comprises administering to said patient a second compound selected from the group consisting of NO donors, phosphodiesterase inhibitors, β-adrenergic receptor agonists, estrogen-like compounds, cGMP-dependent protein kinase activators and cGMP mimetics.
- 21. The method of claim 18, wherein said compound is an α-adrenergic receptor antagonists selected from the group consisting of α1-adrenergic receptor antagonists and α2-adrenergic receptor antagonists.
- 22. The method of claim 21, wherein said α-adrenergic receptor antagonist is an α2-adrenergic receptor antagonist.
- 23. The method of claim 18, wherein said compound is administered orally.
- 24. The method of claim 18, wherein said compound is administered parenterally.
- 25. The method of claim 18, wherein said compound is administered topically.
- 26. The method of claim 25, wherein said compound is in a form selected from the group consisting of gel, ointment, cream, lotion, powder, solution, suspension, spray, paste, oil, suppository, and foam.
- 27. The method of claim 18, wherein said compound is delivered continuously.
- 28. The method of claim 27, wherein a vaginal suppository or a ring impregnated with said compound is inserted at the affected site.
- 29. A method for treating interstitial cystitis, the method comprising administering to a patient in need thereof a compound selected from the group consisting of NO donors, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators, superoxide scavengers, potassium channel activators, testosterone-like compounds, benzodiazepines, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators and endothelin receptor antagonists.
- 30. The method of claim 29, wherein said method comprises administering to said patient at least two compounds.
- 31. The method of claim 29, wherein said method comprises administering to said patient a second compound selected from the group consisting of calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, estrogen-like compounds, adrenergic nerve inhibitors, cGMP-dependent protein kinase activators and cGMP mimetics.
- 32. The method of claim 29, wherein said compound is administered orally.
- 33. The method of claim 29, wherein said compound is administered parenterally.
- 34. The method of claim 29, wherein said compound is administered installation into the bladder.
- 35. The method of claim 29, wherein said compound is administered topically.
- 36. The method of claim 35, wherein said compound is in a form selected from the group consisting of gel, ointment, cream, lotion, powder, solution, suspension, spray, paste, oil, suppository, and foam.
- 37. The method of claim 29, wherein said compound is delivered continuously.
- 38. The method of claim 37, wherein a vaginal suppository or a ring impregnated with said compound is inserted at the affected site.
- 39. A method for treating vulvodynia, the method comprising administering to a patient in need thereof a compound selected from the group consisting of NO donors, calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators, superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators and bisphosphonates.
- 40. The method of claim 39, wherein said method comprises administering to said patient at least two compounds.
- 41. The method of claim 39, wherein said method further comprises administering to said patient a second compound selected from the group consisting of cGMP-dependent protein kinase activators and cGMP mimetics.
- 42. The method of claim 39, wherein said compound is administered orally.
- 43. The method of claim 39, wherein said compound is administered parenterally.
- 44. The method of claim 39, wherein said compound is administered topically.
- 45. The method of claim 44, wherein said compound is in a form selected from the group consisting of gel, ointment, cream, lotion, powder, solution, suspension, spray, paste, oil, suppository, and foam.
- 46. The method of claim 39, wherein said compound is delivered continuously.
- 47. The method of claim 46, wherein a vaginal suppository or a ring impregnated with said compound is inserted at the affected site.
- 48. A method for treating vulvar vestibulitis, the method comprising administering to a patient in need thereof a compound selected from the group consisting of NO donors, calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators, superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators and bisphosphonates.
- 49. A method for treating nonspecific urethritis, the method comprising administering to a patient in need thereof a compound selected from the group consisting of NO donors, calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators, superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors (previously sympathetic nerve terminal destroyers), antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators, endothelin receptor antagonists and bisphosphonates.
- 50. The method of claim 49, wherein said method comprises administering to said patient at least two compounds.
- 51. The method of claim 49, wherein said method further comprises administering to said patient a second compound selected from the group consisting of cGMP-dependent protein kinase activators and cGMP mimetics.
- 52. The method of claim 49, wherein said method further comprises administering to said patient an anti-microbial agent.
- 53. The method of claim 49, wherein said compound is administered orally.
- 54. The method of claim 49, wherein said compound is administered parenterally.
- 55. The method of claim 49, wherein said compound is administered by installation into the bladder.
- 56. The method of claim 49, wherein said compound is administered topically.
- 57. The method of claim 56, wherein said compound is in a form selected from the group consisting of gel, ointment, cream, lotion, powder, solution, suspension, spray, paste, oil, suppository, and foam.
- 58. The method of claim 49, wherein said compound is delivered continuously.
- 59. The method of claim 58, wherein a vaginal suppository or a ring impregnated with said compound is inserted at the affected site.
- 60. A method for treating female sexual arousal disorders, said method comprising administering to a patient in need thereof a compound selected from the group consisting of calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators, superoxide scavengers, potassium channel activators, estrogen-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators and adenylyl cyclase activators.
- 61. The method of claim 60, wherein said method comprises administering to said patient at least two compounds.
- 62. The method of claim 60, wherein said method further comprises administering to said patient a second compound selected from the group consisting of NO donors, testosterone-like compounds, prostaglandin-E1, cGMP-dependent protein kinase activators and cGMP mimetics.
- 63. The method of claim 60, wherein said compound is administered orally.
- 64. The method of claim 60, wherein said compound is administered parenterally.
- 65. The method of claim 60, wherein said compound is administered topically.
- 66. The method of claim 65, wherein said compound is in a form selected from the group consisting of gel, ointment, cream, lotion, powder, solution, suspension, spray, paste, oil, suppository, and foam.
- 67. The method of claim 60, wherein said compound is delivered continuously.
- 68. The method of claim 67, wherein a vaginal suppository or a ring impregnated with said compound is inserted at the affected site.
- 69. A method for treating female sexual orgasmic disorders, said method comprising administering to a patient in need thereof a compound selected from the group consisting of calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators, superoxide scavengers, potassium channel activators, estrogen-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators and adenylyl cyclase activators.
- 70. The method of claim 69, wherein said method comprises administering to said patient at least two compounds.
- 71. The method of claim 69, wherein said method further comprises administering to said patient a second compound selected from the group consisting of NO donors, testosterone-like compounds, prostaglandin-E1, cGMP-dependent protein kinase activators and cGMP mimetics.
- 72. The method of claim 69, wherein said compound is administered orally.
- 73. The method of claim 69, wherein said compound is administered parenterally.
- 74. The method of claim 69, wherein said compound is administered topically.
- 75. The method of claim 74, wherein said compound is in a form selected from the group consisting of gel, ointment, cream, lotion, powder, solution, suspension, spray, paste, oil, suppository, and foam.
- 76. The method of claim 69, wherein said compound is delivered continuously.
- 77. The method of claim 76, wherein a vaginal suppository or a ring impregnated with said compound is inserted at the affected site.
- 78. A method for facilitating a gynecological procedure, the method comprising administering to a patient in need thereof a compound selected from the group consisting of NO donors, calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators, superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators, adenylyl cyclase activators and cGMP-dependent protein kinase activators.
- 79. The method of claim 78, wherein said gynecological procedure is a gynecological exam.
- 80. The method of claim 78, wherein said gynecological procedure is a gynecological surgery.
- 81. The method of claim 78, wherein said compound reduces pain associated with said gynecological procedure.
- 82. A method for increasing a condition selected from the group consisting of vaginal lubrication, clitoral or labial sensitivity and engorgement and relaxation of vaginal smooth muscle, the method comprising administering to a patient in need thereof a compound selected from the group consisting of calcium channel blockers, cholinergic modulators, α-adrenergic receptor antagonists, β-adrenergic receptor agonists, phosphodiesterase inhibitors, cAMP-dependent protein kinase activators, superoxide scavengers, potassium channel activators, estrogen-like compounds, testosterone-like compounds, benzodiazepines, adrenergic nerve inhibitors, antidiarrheal agents, HMG-CoA reductase inhibitors, smooth muscle relaxants, adenosine receptor modulators and adenylyl cyclase activators.
- 83. The method of claim 82, wherein said method further comprises administering to said patient a second compound selected from the group consisting of NO donors, cGMP-dependent protein kinase activators and cGMP mimetics.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] The present application claims priority to U.S. Provisional Pat. Application Nos. 60/273,901, filed Mar. 6, 2001, and 60/334,903, filed Oct. 24, 2001, the teachings of both of which are incorporated herein by reference for all purposes.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60334903 |
Oct 2001 |
US |
|
60273901 |
Mar 2001 |
US |